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ABSTRACT
Myocarditis is an inflammation of the myocardium. The clinical presentations of myocarditis 
range from nonspecific systemic symptom such as fever, myalgias, palpitations, or exertional 
dyspnea, to severe hemodynamic derangement and sudden death. The wide variation of 
clinical manifestations has made the exact incidence of myocarditis difficult to determine. The 
prevalence of myocarditis based on autopsy data is ranging from 2 to 42%. Myocarditis has 
heterogeneous clinical presentation, ranging from mild chest pain or palpitations to cardiogenic 
shock and life-threatening ventricular arrhythmias. The diagnosis of myocarditis requires a 
high initial suspicion. Non-invasive techniques, such as cardiac magnetic resonance imaging, 
can be useful to diagnose and monitor of disease. The endomyocardial biopsy is the gold 
standard for definitive diagnosis of myocarditis and can identify the etiology of myocarditis. By 
endomyocardial biopsy, it can direct patients who can be managed by conventional therapy or 
who require specific treatment based on underlying etiology, such as antiviral or intravenous 
immunoglobulin infusion.
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Introduction
Myocarditis is an inflammation of the 
myocardium. The clinical presentations of 
myocarditis range from nonspecific systemic 
symptom such as fever, myalgias, palpitations, 
or exertional dyspnea, to severe hemodynamic 
derangement and sudden death. The wide 
variation of clinical manifestations has made 
the exact incidence of myocarditis difficult to 
determine. The use of endomyocardial biopsy 
has helped to understand the natural history of 
myocarditis and to clarify the clinicopathological 
correlations.1
The prevalence of myocarditis based on 
autopsy data is ranging from 2 to 42%.2  In 
biopsy-proven myocarditis, the prevalence is 
ranging between 9 and 16% of adult patients 
suffering from idiopathic non-ischaemic dilated 
cardiomyopathy (DCM). In most patients with 
mild symptoms and minimal left ventricular 
dysfunction, myocarditis subside spontaneously 
without specific treatment. However, about 30% 
of cases, in biopsy-proven myocarditis can 
progress to DCM and have a poor prognosis.2 
The aim of the review is to inform the current 
diagnosis and management of myocarditis. 
Definition
Myocarditis refers to every inflammation in 
the myocardium. Inflammation can be occurred 
after any form of injury to the heart, including 
ischemia, mechanical trauma, and genetic 
cardiomyopathies. According to the Dallas criteria, 
acute myocarditis is defined by lymphocytic 
infiltrates in association with myocyte necrosis. 
Borderline myocarditis is defined as inflammatory 
infiltrates without evidence of myocyte necrosis.3 
Newer histologic criteria rely on cell-specific 
immunoperoxidase stains for surface antigens 
such as anti-CD3, anti-CD4, anti-CD20, anti-
CD28, and antihuman leukocyte antigen. The 
criteria based on this type of staining has greater 
sensitivity than the Dallas criteria and may have 
more prognostic value.4
In the 2007 European Society of Cardiology 
(ESC) classifications of cardiomyopathies 
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and the 2013 ESC myocarditis Task Force 
report, myocarditis is defined histologically as 
an inflammatory disease of the myocardium 
diagnosed by endomyocard ia l  b iopsy, 
based on h is to logical ,  immunological , 
immunohistochemical and molecular findings 
to detect possible infectious causes.2,5,6 The term 
inflammatory cardiomyopathy may be used for 
histologically confirmed myocarditis with cardiac 
dysfunction.7
Etiology
The etiology is large variety of infectious 
agents, systemic diseases, drugs, and toxins 
(table 1). Viral infections are the most important 
Table 1. Causes of myocarditis classification
Type Causes Specific
Infectious 1. 
myocarditis
Bacterial Staphylococcus, Streptococcus, Pneumococcus, Meningococcus, 
Gonococcus, Salmonella, Corynebacterium diphtheriae, Haemophilus 
influenzae, Mycobacterium (tuberculosis), Mycoplasma pneumoniae, 
Brucella
Viral RNA viruses: Coxsackieviruses A and B, echoviruses, polioviruses, influenza A 
and B viruses, respiratory syncytial virus, mumps virus,measles virus, rubella 
virus, hepatitis C virus, dengue virus, yellow fever virus, Chikungunya virus, 
Junin virus, Lassa fever virus, rabies
virus, human immunodeficiency virus-1
DNA viruses: adenoviruses, parvovirus B19, cytomegalovirus, human herpes 
virus-6, Epstein-Barr virus, varicella-zoster virus, herpessimplex virus, variola 
virus, vaccinia virus
Spirochaetal Borrelia (Lyme disease), Leptospira (Weil disease)
Fungal Aspergillus, Actinomyces, Blastomyces, Candida, Coccidioides, 
Cryptococcus, Histoplasma, Mucor-mycoses, Nocardia, Sporothrix
Protozoal Trypanosoma cruzi (Chagas disease), Toxoplasma gondii, Entamoeba, 
Leishmania
Parasitic Trichinella spiralis, Echinococcus granulosus, Taenia solium, Schistosoma
Rickettsial Coxiella burnetii (Q fever), R. rickettsii (Rocky Mountain spotted fever), R. 
tsutsugamuschi
Immune-2. 
mediated 
myocarditis
Allergens Tetanus toxoid, vaccines, serum sickness
Drugs: penicillin, cefaclor, colchicine, furosemide, isoniazid, lidocaine, 
tetracycline, sulfonamides, phenytoin, phenylbutazone,methyldopa, thiazide 
diuretics, amitriptyline
Alloantigens Heart transplant rejection
Autoantigens Infection-negative lymphocytic, infection-negative giant cell. Autoimmune 
disorders:systemic lupus erythematosus, rheumatoid arthritis, Churg-
Strausssyndrome, Kawasaki’s disease, inflammatory bowel disease, 
scleroderma, polymyositis, myasthenia gravis, insulin-dependent 
diabetesmellitus, thyrotoxicosis, sarcoidosis, Wegener’s granulomatosis, 
rheumatic heart disease (rheumatic fever)
Toxic 3. 
myocarditis
Drugs Amphetamines, anthracyclines, cocaine, cyclophosphamide, ethanol, 
fluorouracil, lithium, catecholamines, hemetine, interleukin-2,trastuzumab, 
clozapine
Heavy metals Copper, i ron, lead (rare, more commonly cause intramyocyte 
accumulation)
Physical 
agents
Radiation, electric shock, hypothermia, heat stroke
Hormones Phaeochromocytoma, vitamins: beri–beri
Miscellaneous Scorpion sting, snake, and spider bites, bee and wasp stings, carbon 
monoxide, inhalants, phosphorus, arsenic, sodium azide
RNA, ribonucleic acid; DNA, deoxyribonucleic acid; HIV, human immunodeficiensy virus; CMV, cytomegalovirus; 
EBV, Epstein-Barr Virus; HSV, herpes simplex virus (Source: Caforio et al., 2013)2
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cause of myocarditis in North America and 
Europe with genomes of enterovirus, adenovirus, 
influenza viruses, human herpes virus-6 (HHV-6), 
Epstein-Barr-virus, cytomegalovirus, hepatitis 
C virus, and parvovirusB19 reported in the 
myocardium of patients with myocarditis and 
DCM.2 In a multicenter study of 624 patients with 
biopsy-proven myocarditis (66%) or borderline 
myocarditis (34%), evidence of viral genome 
(adenovirus,enterovirus, and cytomegalovirus) 
was detected in 38% of subjects’ endomyocardial 
biopsies.8 Human immunodeficiency virus 
(HIV) has been associated with cardiotropic 
viral infection resulting in myocarditis andl 
eft ventricular dysfunction. It is often unclear 
clinically whether the HIV virus itself, medications 
used for treatment, or myocardial coinfection 
is responsible for the observed left ventricular 
systolic dysfunction due to myocarditis.9
In the myocarditis, if no viruses are identified 
in endomyocardial biopsy and other known 
causes are excluded, lymphocytic and giant 
cell myocarditis are presumed idiopathic or 
autoimmune. Similarly, the diagnosis of idiopathic 
granulomatous myocarditis (cardiac sarcoidosis) 
requires negative stains for microorganisms. 
Figure 1. Pathogenesis process of myocarditis (Source: Cooper, 
2009)11
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Autoimmune myocarditis can be exclusively 
cardiac involvement or as a part of autoimmune 
disorders with extra-cardiac manifestations, such 
as in sarcoidosis, hypereosinophilic syndrome, 
scleroderma, and systemic lupus erythematosus. 
Autoimmune myocarditis is a primary antigen 
responsible for progression from a self-limited viral 
infection to subsequent autoimmune disease.10
The bacterial-induced myocarditis is far 
less common than viral-induced myocarditis. 
Toxin-producing bacteria, including clostridium 
and diphtheria, can cause severe myocardial 
damage. Bacteremia from any source may result in 
myocarditis. The most common is meningococcus, 
streptococcus, and Listeria. Regional wall-motion 
abnormalities or perfusion defects that are not in 
the distribution of a coronary artery may also be 
seen in noninfectious disorders, such as cardiac 
sarcoidosis and arrhythmogenic right ventricular 
cardiomyopathy or dysplasia.11
Drug-induced hypersensitivity reactions 
and systemic hypereosinophilic syndromes 
can cause a specific myocarditis.  Numerous 
medications, including some anticonvulsants, 
antibiotics, and antipsychotics, have been 
associated with hypersensitivity myocarditis.12 
Eosinophilic myocarditis is characterized by a 
largely eosinophilic infiltrate in the myocardium. It 
may occur in association with systemic diseases, 
such as the hypereosinophilic syndrome, the 
Churg-Strauss syndrome, Löffler’s endomyocardial 
fibrosis, cancer, and parasitic, helminthic, or 
protozoal infections.12 Clinical manifestations 
of eosinophilic myocarditis include congestive 
heart failure, endocardial and valvular fibrosis, 
and endocardial thrombi. A rare disorder, acute 
necrotizing eosinophilic myocarditis is a progressive 
form of eosinophilic myocarditis with an acute onset 
and a high fatality rate.12
Other substances other than infectious 
agents can affect on the heart and injure the 
myocardium. In some cases, the damage is 
acute, transient, and associated with evidence 
of an inflammatory myocardial infiltrate with 
myocyte necrosis. Other agents that harm 
the myocardium can lead to chronic changes 
with resulting histologic evidence of fibrosis 
and a clinical picture of a dilated or restrictive 
Figure 2. Pathogenesis of myocarditis (Source: Blauwet & Cooper, 2010)13
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cardiomyopathy.13 Radiation therapy canlead 
to a variety of cardiac complications that arise 
long after the completion of radiation therapy, 
including pericarditis with effusion, tamponade, 
or constrict ion; coronary artery f ibrosis 
andmyocardial infarction; valvular abnormalities; 
myocardial fibrosis; and conduction disturbances. 
Radiation-induced cardiac damage is related to 
the cumulative dose of the radiation, and the 
mass of heart irradiated.13
Pathogenesis
The pathogenesis of viral myocarditis can be 
divided into three major components: viral infection 
and replication, immunologic response (innate and 
adaptive immune response), and phase of cardiac 
remodeling or recovery14 (figure 1).
Viruses enter the host through a variety of 
locations including the gastrointestinal system or 
the respiratory system. The virus binds to a viral 
receptor, ultimately resulting in internalization 
of the virus. This process includes entry of the 
viral capsid proteins and the viral genome. The 
virus may undergo initial replication in the host 
in organs such as the liver,spleen and pancreas. 
Ultimately, the virus reaches the heart via 
dissemination through the blood orlymphatic 
vessels.13
After viral entry acute injury of the myocytes, 
induced by virus replication leads to myocyte 
necrosis, exposure of intracellular antigens (e.g. 
Table 2. Clinical Presentations of Patients with Inflammatory Heart Muscle Disease
 Acute coronary syndrome-like1. 
(a) Acute chest pain
Frequently starting within 1–4 weeks of a respiratory or gastrointestinal infection- 
Frequently associated with severe and recurrent symptoms- 
In the absence of angiographic evidence of CAD- 
(b) ST/T wave changes
ST-segment elevation or depression- 
T-wave inversions- 
(c)  With or without normal global or regional LV and/or RV dysfunction on echocardiography or CMR
(d) With or without increased TnT/TnI that may have a time course similar to acute myocardial infarction 
or a prolonged and sustained release over severalweeks or months
New onset or worsening heart failure in the absence of CAD and known causes of heart failure2. 
(a) New onset or progressive heart failure over 2 weeks to 3 months
Dyspnoea- 
Peripheral oedema- 
Chest discomfort- 
Fatigue- 
(b) Impaired systolic LV and/or RV function, with or without an increase in wall thickness, with or without 
dilated LV and/or RV on echocardiography or CMR
(c) Symptoms possibly started after a respiratory or gastrointestinal infection, or in the peri-partum 
period
(d) Non-specific ECG signs, bundle branch block, AV-block, and/or ventricular arrhythmias
Chronic heart failure in the absence of CAD and known causes of heart failure3. 
(a) Heart failure symptoms (with recurrent exacerbations) of >3 months duration
(b) Fatigue, palpitation, dyspnoea, atypical chest pain, arrhythmia in an ambulant patient
(c) Impaired systolic LV and/or RV function on echocardiography or CMR suggestive of DCM or non-
ischaemic cardiomyopathy
(d) Non-specific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-
block
‘life-threatening condition’, in the absence of CAD and known causes of heart failure comprising4. 
(a) Life-threatening arrhythmias and aborted sudden death
(b) Cardiogenic shock
(c) Severely impaired LV function
(Source: Caforio et al., 2013)2
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cardiac myosin), and activation of the host’s 
immune system, which is characterized by the 
invasion of natural killer cells and macrophages 
followed by T lymphocytes. The acute phase 
of myocarditis takes only a few days. After the 
acute phase of virus-induced injury, the second 
phase is characterized by immune reactions. 
Cytokine activation and antibodies to viral and 
cardiac proteins may worsen cardiac damage 
and cause injury of the contractile function. The 
balance of immune response by the host is a 
major determinant of patient outcome.15 The fisrt 
host responses to the viral are the innate immune 
system. Activation of acquired immunity can lead 
to the production of T-killer cells that can directly 
damage the virus and virally infected cells. The 
activation of T cells also leads to the activation of 
B cells and the production of specific antibodies 
to neutralise the antigen. This response results in 
subacute and chronic inflammation in myocarditis 
and contributes to the subsequent myocyte 
necrosis, fibrosis, and remodelling.16
If the inflammatory response persists, the 
heart can endure remodelling. It is a modification 
of the cardiac structure and function, which leads to 
the development of dilated cardiomyopathy (figure 
2). The inflammatory  process  from  both  innate 
and acquired  immunity  can  lead to release of 
cytokines, which are potent activators of matrix 
metalloproteinases that can digest the interstitial 
collagen and elastin in the heart. The final result is 
dilated cardiomyopathy, with systolic and diastolic 
dysfunction, and progressive heart failure.13
Clinical Presentation
Myocarditis clinical presentation is ranging 
from mild symptoms, such as chest pain and 
palpitations to life-threatening cardiogenic shock 
and ventricular arrhythmia. The disease may 
affect individuals of all ages, with most frequently 
occurring in the young.2 This diversity of clinical 
presentation implicates that the diagnosis of 
myocarditis requires a high level of suspicion 
early in the course of the disease. In all cases of 
suspected myocarditis, it is mandatory to exclude 
coronary artery disease and other cardiovascular 
disease that could explain the clinical presentation. 
If this is strongly suspected by theclinician, further 
investigation including endomyocardial biopsy may 
be proper diagnostic tool.2
Myocarditis should be suspected in a 
previously asymptomatic young subject with 
few coronary artery disease risk factors who, 
days or weeks after a supposed respiratory 
or gastrointestinal viral syndrome, develops 
dyspnoea or orthopnoea, or palpitations, or 
effort intolerance/malaise, or heart failure, or 
Table 3. Diagnostic criteria for clinically suspected myocarditis
ECG/Holter/stress test featuresI. 
     Newly abnormal 12 lead ECG and/or Holterand/or stresstesting, any of the following: I to III degree 
atrioventricular block, or bundle branch block, ST/T wave change (ST elevation or non ST elevation, T 
wave inversion), sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial fibrillation, reduced 
R wave height, intraventricular conduction delay (widened QRS complex), abnormal Q waves, low voltage, 
frequent premature beats, supraventricular tachycardia
Myocardiocytolysis markersII. 
       Elevated Troponin T/I
Functional and structural abnormalities on cardiac imaging (echo/angio/CMRIII. )
         New, otherwise unexplained LV and/ or RV structure and function abnormality (including incidental finding 
in apparently asymptomatic subjects): regional wall motion or global systolic or diastolic function abnormality, 
with or without ventricular dilatation, with or without increased wall thickness, with or without pericardial 
effusion, with or without endocavitary thrombi
Tissue characterization by CMRIV. 
       Oedema and/or LGE of classical myocarditic pattern
(Source: Caforio et al., 2013)2
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chest pain (which may be pleuritic if concomitant 
pericarditisis present) with or without cardiac 
troponin I orT (cTNI or cTNT) release and 
unobstructed coronary arteries at coronary 
angiography.17 The clinical manifestation of 
myocarditis varies ranging from asymptomatic 
coursesto presentations with signs of myocardial 
infarction to devastating illness with cardiogenic 
shock. Chest pain, cardiac arrhythmias, and 
acute or chronic heart failure can occur during 
the course of the disease.18
Diagnosis
Non-invasive imaging techniques such as 
cardiac magnetic resonance (CMR) imaging can 
be useful in making the diagnosis of myocarditis 
and for monitoring disease progression. However, 
endomyocardial biopsty is the gold standard 
for the diagnosis of definite myocarditis. In 
order to improve recognition of myocarditis in 
clinical practice and to aid selection of patients 
that require further diagnostic evaluation and 
treatment, the working group proposed new 
criteria for clinically suspected myocarditis for 
which biopsy analysis is recommended (table 
3).
Myocarditis should be suspected in the 
presence of2:
1 or more of the clinical presentations in table  ♦
3, with or without ancillary features 
1 or more of the diagnostic criteria from  ♦
different categories (I to IV) in table 3
when the patient is asymptomatic, 2 or more  ♦
diagnostic criteria from different categories 
(I to IV)
Ancillary features which support the clinical 
suspicion of myocarditis include:
fever ≥38 ♦ 0C at presentation or within the 
preceding 30 days with or without evidence 
of a respiratory (chills, headache, muscle 
aches, general malaise) or gastrointestinal 
(decreased appetite, nausea, vomiting, 
diarrhoea) infection
peri-partum period ♦
previous clinically suspected or definite  ♦
myocarditis (according to the criteria set in 
Table 3)
personal and/ or family history of allergic  ♦
asthma, other types of allergy, extra-cardiac 
autoimmune disease, toxic agents
family history of DCM, myocarditis (according  ♦
to the present criteria).
These criteria are based upon consensus 
of experts. The hospital that can not perform 
endomyocardial biopsy or do not have access 
to state-of-the-art CMR should refer patients 
with clinically suspected myocarditis to a tertiary 
referral unit experienced in endomyocardial biopsy 
and CMR, particularly when patientspresent with 
haemodynamic instability or life-threatening 
arrhythmia. In patients fulfilling the diagnostic 
criteria for clinically suspected myocarditis, 
it is recommended to selective coronary 
angiography and endomyocardial biopsy. This 
recommendation also applies to patients with an 
acute coronary syndrome-like presentation.2
The Electrocardiography Examination
The electrocardiogram (ECG) is widely 
used as a screening tool despite low sensitivity. 
The ECG findings in patients with myocarditis 
vary from non specific T-wave and ST-segment 
changes mimicking an acute myocardial 
infarction. It includes ST-segment elevation in 
≥ 2 contiguous leads (54%), T-wave inversions 
(27%), widespread ST-segment depressions 
(18%), and pathological Q waves (18% to 
27%). Atrial or ventricular conduction defect, 
supraventricular and ventricular arrhythmias can 
occur in patients with myocarditis. The presence 
of Qwaves or a new left bundle branch block are 
associated with higher rates of cardiac death or 
heart transplantation.1 A QTc prolongation >440 
ms, abnormal QRS axis, and ventricularectopic 
beats are associated with poor clinical outcome. 
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A prolonged QRS duration of >120 ms is an 
independent predictor for cardiac death or heart 
transplantation. Hence, the ECG represents 
an easily available tool for risk stratification in 
patients with suspected myocarditis.15
The Echocardiography Examination
Echocardiography helps to rule out non-
inflammatory cardiac disease such as valve 
disease and to monitor changes in cardiac 
chamber size, wall thickness, ventricular 
function, pericardial effusions and the presence 
of intracavitary thrombi. Global ventricular 
dysfunction,regional wall motion abnormalities, 
and diastolic dysfunction with preserved ejection 
fraction may occur in myocarditis. Myocarditis 
may be similar to dilated, hypertrophic, and 
restrictive cardiomyopathy. It may also mimic 
ischaemic heart disease. Fulminant myocarditis 
often presents with a non-dilated, thickened, and 
hypocontractile left ventricle, because of severe 
inflammatory response results in interstitial 
oedema and loss of ventricular contractility.2
Pericardial effusions suggestive of 
myopericarditis may also be observed and help 
to make a diagnosis. Diastolic filling patterns 
are abnormal in most patients, with a restrictive 
pattern frequently present. Right ventricular 
dysfunction may present in only the minority of 
patients. Segmental wall motion abnormalities 
may be observed in more than half of patients, 
which included hypokinetic, akinetic, or dyskinetic 
regional pattern. Reversible left ventricular 
hypertrophy is  observed in a few patients and 
typically resolved over several months. Thus, 
echocardiographic findings can be varied but 
relatively nonspecific.1
The Biomarker Examination
The b iomarker  for  myocard i t is  is 
non specific. Cardiac troponins are highly 
suggestive of acute myocarditis, when other 
potential causes of myocardial necrosis have 
been excluded. NT-pro-BNP or BNP levels 
should be measured when heart failure is 
suspected, but normal values do not exclude 
myocarditis. Newer cardiac biomarkers, such 
as copeptin or midregional pro- adrenomedullin, 
do not provide addit ional diagnostic or 
prognostic information. Nonspecific markers of 
inflammation (white blood cellcount, C-reactive 
protein, and erythrocyte sedimentation rate) 
are often elevated in myocarditis.19 Positive 
viral serology does not imply myocardial 
infection but rather indicates the interaction of 
the immune system with an infectious agent. 
Antibodies of IgG class, which are shown to be 
cardiac and disease-specific for myocarditis, 
can be used as autoimmune biomarkers for 
identifying at risk relatives and those patients 
in whom, in the absence of active infection of 
the myocardium, immunosuppression and/or 
immunomodulation may be beneficial.2
The endomyocardial biopsy
The gold standard in diagnosis of myocarditis 
is still the endomyocardial biopsy. Endomyocardial 
biopsy confirms the diagnosis of myocarditis 
and identifies the underlying aetiology and the 
type of inflammation (e.g. giant cell, eosinophilic 
myocarditis, sarcoidosis). It imply different 
treatments and prognosis. If endomyocardial 
biopsy is performed by experienced teams, the 
complication rate is very low (0–0,8%).15
The 2007 American Heart Association/
American College of Cardiology Foundation/
European Society of Cardiology scientific 
statement on endomyocardial biopsy limited its 
class I recommendations to unexplained new-
onset heart failure of less than 2 weeks duration 
associated with hemodynamic compromise or 
unexplained new-onset heart failure of 2 weeks 
to 3 months duration associated with a dilated 
left ventricle and new ventricular arrhythmias or 
conduction disturbances.6 However, in a recent 
position statement from the 2013 European 
Society of Cardiology, the recommendation for 
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endomyocardial biopsy is extended, including 
patients with a pseudo-infarct presentation after 
exclusion of coronary artery disease.2 
The complications of endomyocardial biopsy 
include hematoma, arteriovenous fistula, vasovagal 
reaction, pneumothorax,arrhythmia, heart block, 
infection, tricuspid valve damage,pulmonary 
embolism or systemic embolism during left 
ventricular biopsy, and cardiac chamber perforation 
with possible hemopericardium and cardiac 
tamponade.20 Left ventricular biopsy has also been 
proven to be a safe procedure. The complications is 
only occurred in 0.33 % of patients who underwent 
left ventricular endomyocardial biopsy.21 
The Imaging Examination
Cardiovascular magnetic resonance 
(CMR) imaging provides non-invasivetissue 
characterization of the myocardium and can 
support the diagnosis of myocarditis. The timing 
of CMR in suspected myocarditis will depend 
upon local availability and expertise, but it is 
reasonable to first perform CMR in clinically 
stable patients, prior to endomyocardial biopsy. 
CMR findings are consistent with myocardial 
inflammation, if at least two of the following 
criteria are present:
Regional or global myocardial signal intensity 1) 
increase in T2-weighted oedema images
Increased global myocardial early gadolinium 2) 
enhancement ratio between myocardium 
and skeletal muscle in gadolinium-enhanced 
T1-weighted images
There is at least one focal lesion with non-3) 
ischaemic regional distribution in inversion 
recovery-prepared gadolinium-enhanced 
T1-weighted images (late gadolinium 
enhancement)
 When at least criteria are met, a sensitivity 
of 76% and specificity of 96% have been 
reported in patients with clinically suspected 
acute myocarditis and pseudoinfarction 
presentation. A repeat CMR study between 
1 and 2 weeks after the initial CMR study is 
recommended if:
None of the criteria are present, but the a) 
onset of symptoms has been very recent 
and there is strong clinical evidence for 
myocardial inflammation
Figure 3. Myocarditis treatment according to clinical setting and endomyocardial biopsy results 
(Source: Dominguez et al., 2016)19
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One of the criteria is presentb) 
 The presence of left ventricle dysfunction 
or pericardial effusion provides additional, 
supportive evidence for myocarditis.2
Recent studies have shown good 
correlat ions between CMR results and 
endomyocardial biopsy in acute myocarditis. 
However, obtaining the biopsy from the region of 
late gadolinium enhancement of the CMR has not 
proven to increase the yield of diagnosis and in 
chronic myocarditis, the diagnostic performance 
of CMR was found to be worse (sensitivity 63%; 
specificity 40%).15 Therefore, CMR might not 
be appropriate to guide clinical management in 
chronic myocarditis. The detailed information 
about the degree of inflammation, the presence 
of special forms ofmyocarditis (e.g., giant cell or 
eosinophilic myocarditis, which require specific 
therapies), or the presence and type of virus is 
not available in CMR.15
MANAGEMENT
Outcome and prognosis of myocarditis 
depends on aetiology, clinical presentation 
and disease stage. Acute myocarditis resolves 
in about 50% of cases in the first 2–4 weeks, 
but about 25% will develop persistent cardiac 
dysfunction and 12–25% may acutely deteriorate 
and fatal or progress to end-stage dilated 
cardiomyopathy. Biventricular dysfunction at 
presentation has been reported as the main 
predictor of death or transplantation. Fulminant 
myocarditis of unknown aetiology is more 
frequent in children and far less in adults.2
Conventional Medical Treatment
Patients with haemodynamically unstable 
heart failure should be cared promptly according 
to current ESC guidelines for heart failure 
in intensive care units with respiratory and 
mechanical cardio-pulmonary support facilities.22 
In acute/fulminant cases withcardiogenic shock 
and severe ventricular dysfunction, ventricular 
assist devices or extracorporeal membrane 
oxygenation (ECMO) may be needed to provide 
a bridge to transplant or to recovery. Because of 
its simplicity and effectiveness, ECMO therapy 
can be salvaged this group of patients.22
When myocardit is is suspected in 
asymptomatic or mildly symptomatic patients, 
admission to the hospital and clinical monitoring 
are recommended until a definite diagnosis 
is established. The need for monitoring is 
mandatory, since the clinical condition can evolve 
rapidly and a cardiopulmonary emergency (e.g. 
severe heart block or life-threatening arrhythmia) 
is treatening and unpredictable. Exercise 
testing is contraindicated in the acute stage 
as it can precipitate arrhythmia.19 Patients with 
haemodynamically stable heart failure should 
be treated with diuretics, angiotensin-converting 
enzyme inhibitor, or angiotensin receptor 
blockade and beta-adrenergic blockade.19 
In patients who have persistent heart failure 
symptoms in spite of optimal management, 
additional treatment with aldosterone antagonists 
should be considered. The procedure for weaning 
of heart failure therapy following recovery of 
ventricular function is not clearly defined. The 
use of non-steroidal anti-inflammatory drugs, in 
particular acetylsalicylic acid, are a cornerstone 
of treatment for acute pericarditis, but have 
been associated with increased mortality in 
experimental models of myocarditis.2,19
There are no specific recommendations for 
the management of arrhythmia in myocarditis, 
and so management should be in line withcurrent 
ESC guidelines. Sinus bradycardia, prolonged 
QRS duration, increased left ventricular 
hypokinesis on echocardiography, may precede 
a life-threatening arrhythmia.2 Temporary 
pacing may be needed for complete atrio-
ventricular block. Indication for cardioverter 
defibrillator implantation (ICD) is controversial, 
because myocarditis may resolve completely.19 
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Physical activity should be restricted during the 
acute phase of myocarditis until the disease 
has completely resolved. After resolution of the 
clinical presentation (at least 6 months after the 
onset of the disease), clinical reassessment is 
indicated before resumes competitive activity 
for athletes and non-athletes.2
Specific Medical Treatments
Autoimmune/ Virus Negative
In some patients, inflammation persists, 
despite viral clearance In these patients, the 
inflammatory process is due to a post-infectious 
state or autoimmunity. Some randomized trials 
have shown that immunosuppressive therapy 
in these patients is superior to conventional 
treatment alone in terms of LV ejection fraction 
and NYHA classification improvement.23 In the 
TIMIC study,23 chronic myocarditis virus-negative 
patients with less than 45% LV ejection fraction 
who received conventional heart failure for at 
least 6 months were randomized to placebo 
vs cortisone and azathioprine. The LV ejection 
fraction improved in 89% of patients from the 
treatment group and in none in the placebo 
group. Furthermore, a previous study observed 
that only virus-negative patients improve with 
immunosupression.23
Viral Cardiomyopathy
There is still no approved antiviral-therapy 
for the treatment of viral myocarditis. Treatment 
with acyclovir, gancyclovir, and valacyclovir may 
beconsidered in patients with herpes virus infection, 
although theirefficacy is unproven in myocarditis.2 
Preliminary data on interferon-beta (IFN-ß) 
treatment suggest that it eliminates enteroviral and 
adenoviralgenomes in patients with left ventricular 
dysfunction, is associated with improvement in 
NYHA functional class and specifically inenteroviral 
infection, with a better 10-year prognosis.2
Among patients with chronic enteroviral 
or adenoviral cardiomyopathy, viral clearance 
with a 6-month course of IFN-ß therapy 
was accompanied by LV ejection fraction 
improvement and a significant decrease of 
ventricular dimensions in non-randomized 
trial.24 The patients who cleared the virus 
spontaneously had higher levels of endogenous 
IFN-ß than those with viral presently persist.24 
Thus, these findings support the efficacy of 
IFN-ß therapy.19 
High dose intravenous immunoglobulin 
(IVIG) modulates the immune and inflammatory 
response by a variety of mechanisms and is 
used in a number of systemic autoimmune 
diseases. Its use has been associated with 
improved LV ejection fraction in chronic 
symptomatic heart failure of various causes, but 
IVIG was ineffective in the recent-onset dilated 
cardiomyopathy in which only 15% of patients 
had biopsy-proven myocarditis of non-specified 
cause.2 IVIG may be used in myocarditis 
refractory to conventional heart failure therapy, 
both viral and autoimmune forms, particularly if 
autoantibody-mediated.2
Prognosis
Myocarditis patients can have partial or 
full clinical recovery; some may relapse many 
years after the first episode. Relapses should be 
managed similarly to the previous myocarditis 
episode. In patients who do not resolve, disease 
may continue subclinically and lead to dilated 
cardiomyopathy. The myocarditis patient with 
pseudo-infact presentation, normal coronary 
arteries, and preserved ventricular function may 
be safely discharged when cardiac enzymes 
have come into the normal range, and shoul be 
long-term followed-up. In the event of prolonged 
(weeks or even months) documented increase of 
cardiac enzymes, and/or progressive reduction 
in left and/or rightventricular function, the patient 
should be readmitted to hospital to perform 
endomyocardial biopsy.2
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Conclusion
Myocarditis is an inflammation of the heart 
muscle that can be found after the injury either 
because of exposure to external antigens, such 
as viruses, bacteria, parasites, toxins, or drugs, 
as well as internal boosters such as autoimmune 
activation. Myocarditis has heterogeneous 
clinical presentation, ranging from mild chest 
pain or palpitations to cardiogenic shock and 
life-threatening ventricular arrhythmias. The 
diagnosis of myocarditis requires a high initial 
suspicion. Non-invasive techniques, such as 
CMR, can be useful to diagnose and monitor of 
disease. The endomyocardial biopsy is the gold 
standard for definitive diagnosis of myocarditis 
and can identify the etiology of myocarditis. By 
endomyocardial biopsy, it can direct patients who 
can be managed by conventional therapy or who 
require specific treatment based on underlying 
etiology, such as antiviral or IVIG.
References
Magnani JW, Dec GW. 2006. Myocarditis: 1. 
current trends in diagnosis and treatment. 
Circulation. 113(6):876-890.
Caforio AL, Pankuweit S, Arbustini E, Basso 2. 
C, Gimeno-Blanes J, Felix SB, et al. 2013. 
Current state of knowledge on aetiology, 
diagnosis, management, and therapy of 
myocarditis: a position statement of the 
European Society of Cardiology Working 
Group on Myocardial and Pericardial 
Diseases. Eur Heart J. 34(33):2636-2648.
Aretz HT, Billingham ME, Edwards WD, 3. 
Factor SM, Fallon JT, Fenoglio JJ, Jr., et 
al. 1987. Myocarditis. A histopathologic 
definition and classification. Am J Cardiovasc 
Pathol. 1(1):3-14.
Baughman KL.  2006.  Diagnos is  o f 4. 
myocarditis: death of Dallas criteria. 
Circulation. 113(4):593-595.
Richardson P, McKenna W, Bristow M, Maisch 5. 
B, Mautner B, O'Connell J, et al. 1996. Report 
of the 1995 World Health Organization/
International Society and Federation of 
Cardiology Task Force on the Definition 
and Classification of Cardiomyopathies. 
Circulation. 93(5):841-842.
Elliott P, Andersson B, Arbustini E, Bilinska Z, 6. 
Cecchi F, Charron P, et al. 2008. Classification 
of the cardiomyopathies: a position statement 
from the European Society Of Cardiology 
Working Group on Myocardial and Pericardial 
Diseases. Eur Heart J. 29(2):270-276.
Leone O, Veinot JP, Angelini A, Baandrup 7. 
UT, Basso C, Berry G, et al. 2012. 2011 
consensus statement on endomyocardial 
biopsy from the Association for European 
Cardiovascular Pathology and the Society 
for Cardiovascular Pathology. Cardiovasc 
Pathol. 21(4):245-274.
Bowles NE, Ni J, Kearney DL, Pauschinger 8. 
M, Schultheiss HP, McCarthy R, et al. 2003. 
Detection of viruses in myocardial tissues 
by polymerase chain reaction. evidence 
of adenovirus as a common cause of 
myocarditis in children and adults. J Am Coll 
Cardiol. 42(3):466-472.
Barbaro G, Di Lorenzo G, Grisorio B, 9. 
Barbarini G. 1998. Incidence of dilated 
cardiomyopathy and detection of HIV in 
myocardial cells of HIV-positive patients. 
Gruppo Italiano per lo Studio Cardiologico 
dei Pazienti Affetti da AIDS. N Engl J Med. 
339(16):1093-1099.
Rose NR. 2009. Myocarditis: infection versus 10. 
autoimmunity. J Clin Immunol. 29(6):730-
737.
Cooper LT, Jr. 2009. Myocarditis. N Engl J 11. 
Med. 360(15):1526-1538.
Corradi D, Vaglio A, Maestri R, Legname 12. 
V, Leonardi G, Bartoloni G, et al. 2004. 
Eosinophilic myocarditis in a patient with 
81  
Acta Cardiologia Indonesiana (Vol 2 No. 2): 69-81
Copyright©2013. Jurnal Perikanan (Journal of Fisheries Sciences) All Right Reserved
idiopathic hypereosinophilic syndrome: 
insights into mechanisms of myocardial cell 
death. Hum Pathol. 35(9):1160-1163.
Blauwet LA, Cooper LT. 2010. Myocarditis. 13. 
Prog in Cardiovasc Dis. 52(4):274-288.
Bonow R, Mann D, Zipes D, Libby P. 2012. 14. 
Braunwald's Heart Disease: A Textbook 
of Cardiovascular Medicine. Ninth ed. 
Philadelphia: Elsevier Saunders. pp.1589-
1602
Kindermann I, Barth C, Mahfoud F, Ukena 15. 
C, Lenski M, Yilmaz A, et al. 2012. Update 
on myocarditis. J Am Coll Cardiol. 59(9):779-
792.
Sagar S, Liu PP, Cooper LT, Jr. 2012. 16. 
Myocarditis. The Lancet. 379(9817):738-
747.
Caforio AL, Marcolongo R, Basso C, Iliceto S. 17. 
2015. Clinical presentation and diagnosis of 
myocarditis. Heart. 101(16):1332-1344.
Canter CE, Simpson KP. 2014. Diagnosis 18. 
and treatment of myocarditis in children in the 
current era. Circulation. 129(1):115-128.
Dominguez F, Kühl U, Pieske B, Garcia-Pavia 19. 
P, Tschöpe C. 2016. Update on Myocarditis and 
Inflammatory Cardiomyopathy: Reemergence 
of Endomyocardial Biopsy. Revista Española 
de Cardiología (English Edition). 69(02):178-
187.
Holzmann M, Nicko A, Kuhl U, Noutsias 20. 
M, Poller W, Hoffmann W, et al. 2008. 
Complication rate of right ventricular 
endomyocardial biopsy via the femoral 
approach: a retrospective and prospective 
study analyzing 3048 diagnostic procedures 
over an 11-year period. Circulat ion. 
118(17):1722-1728.
Chimenti C, Frustaci A. 2013. Contribution 21. 
and risks of left ventricular endomyocardial 
biopsy in patients with cardiomyopathies: a 
retrospective study over a 28-year period. 
Circulation. 128(14):1531-1541.
Mirabel M, Luyt CE, Leprince P, Trouillet JL, 22. 
Leger P, Pavie A, et al. 2011. Outcomes, 
long-term quality of life, and psychologic 
assessment of fulminant myocarditis patients 
rescued by mechanical circulatory support. 
Crit Care Med. 39(5):1029-1035.
Frustaci A, Russo MA, Chimenti C. 2009. 23. 
Randomized study on the efficacy of immuno-
suppressive therapy in patients with virus-
negative inflammatory cardiomyopathy: the 
TIMIC study. Eur Heart J. 30(16):1995-2002.
Kühl U, Lassner D, von Schlippenbach J, 24. 
Poller W, Schultheiss HP. 2012. Interferon-
beta improves survival in enterovirus-
associated cardiomyopathy. J Am Col 
Cardiol. 60(14):1295-1296.
